KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Free Cash Flow (2020 - 2026)

AbCellera Biologics filings provide 7 years of Free Cash Flow readings, the most recent being -$37.4 million for Q1 2026.

  • Quarterly Free Cash Flow fell 68.34% to -$37.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$189.2 million through Mar 2026, down 32.06% year-over-year, with the annual reading at -$174.1 million for FY2025, 6.89% up from the prior year.
  • Free Cash Flow hit -$37.4 million in Q1 2026 for AbCellera Biologics, up from -$44.6 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $241.7 million in Q2 2022 and bottomed at -$139.3 million in Q3 2022.
  • Average Free Cash Flow over 5 years is -$18.4 million, with a median of -$37.4 million recorded in 2026.
  • Peak annual rise in Free Cash Flow hit 171.08% in 2022, while the deepest fall reached 860.29% in 2022.
  • AbCellera Biologics' Free Cash Flow stood at $18.6 million in 2022, then crashed by 283.2% to -$34.0 million in 2023, then skyrocketed by 30.59% to -$23.6 million in 2024, then tumbled by 88.68% to -$44.6 million in 2025, then rose by 16.22% to -$37.4 million in 2026.
  • Per Business Quant, the three most recent readings for ABCL's Free Cash Flow are -$37.4 million (Q1 2026), -$44.6 million (Q4 2025), and -$61.5 million (Q3 2025).